Citi said the acceptance of Abatacept indicated the most challenging development and biosimilar hurdles were behind for the company in terms of the biological license application (BLA).
Citi said the acceptance of Abatacept indicated the most challenging development and biosimilar hurdles were behind for the company in terms of the biological license application (BLA).